# iBio, Inc.: financial statements, quarterly

IBIO · Nasdaq · CIK 1420720 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/ibio.md) · [Financials](/companies/ibio/financials.md) · [Filings](/companies/ibio/filings.md) · [Insiders](/companies/ibio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ibio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001420720-24-000054.md) | [0.0 d](/filings/0001420720-25-000012.md) | [0.0 d](/filings/0001420720-25-000025.md) | [0.2 d](/filings/0001558370-25-011888.md) | [0.0](/filings/0001420720-25-000043.md) | [0.2](/filings/0001420720-26-000004.md) | [0.0](/filings/0001420720-25-000025.md) | [0.2 d](/filings/0001420720-26-000020.md) | [0.1](/filings/0001420720-25-000043.md) | [0.0](/filings/0001420720-26-000004.md) | [0.0 d](/filings/0001104659-26-059416.md) | [0.0 d](/filings/0001420720-26-000020.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.6](/filings/0001420720-24-000054.md) | [1.5](/filings/0001420720-25-000012.md) | [0.9](/filings/0001420720-25-000025.md) | [1.1 d](/filings/0001558370-25-011888.md) | [1.3](/filings/0001420720-25-000043.md) | [1.9](/filings/0001420720-26-000004.md) | [1.9](/filings/0001104659-26-059416.md) | [3.2 d](/filings/0001420720-26-000020.md) | [3.6](/filings/0001420720-25-000043.md) | [4.3](/filings/0001420720-26-000004.md) | [3.3](/filings/0001104659-26-059416.md) | [8.6 d](/filings/0001420720-26-000020.md) |
| Operating income | $m | [(5.1)](/filings/0001420720-24-000054.md) | [(4.5)](/filings/0001420720-25-000012.md) | [(3.6)](/filings/0001420720-25-000025.md) | [(3.4) d](/filings/0001558370-25-011888.md) | [(4.1)](/filings/0001420720-25-000043.md) | [(4.4)](/filings/0001420720-26-000004.md) | [(4.9)](/filings/0001104659-26-059416.md) | [(5.2) d](/filings/0001420720-26-000020.md) | [(6.0)](/filings/0001420720-25-000043.md) | [(9.4)](/filings/0001420720-26-000004.md) | [(8.4)](/filings/0001104659-26-059416.md) | [(11.4) d](/filings/0001420720-26-000020.md) |
| Interest expense | $m | [0.0](/filings/0001558370-23-019043.md) | [0.0](/filings/0001558370-24-000934.md) | [0.1](/filings/0001420720-24-000020.md) | [0.1 d](/filings/0001558370-25-011888.md) | [0.1](/filings/0001420720-25-000043.md) | [0.1](/filings/0001420720-26-000004.md) | [0.1](/filings/0001104659-26-059416.md) | [0.0 d](/filings/0001420720-26-000020.md) | [0.0](/filings/0001420720-25-000043.md) | [0.0](/filings/0001420720-26-000004.md) | [0.0](/filings/0001104659-26-059416.md) | [(0.0) d](/filings/0001420720-26-000020.md) |
| Income tax | $m | [0.0](/filings/0001420720-24-000054.md) | [0.0](/filings/0001558370-24-000934.md) | [0.0](/filings/0001420720-25-000025.md) | [0.0 d](/filings/0001558370-25-011888.md) | [0.0](/filings/0001420720-25-000043.md) | [0.0](/filings/0001420720-26-000004.md) | [0.0](/filings/0001104659-26-059416.md) | [0.0 d](/filings/0001420720-26-000020.md) | [0.0](/filings/0001420720-25-000043.md) | [0.0](/filings/0001420720-26-000004.md) | [0.0](/filings/0001104659-26-059416.md) | [0.0 d](/filings/0001420720-26-000020.md) |
| Net income | $m | [(5.7)](/filings/0001420720-25-000025.md) | [(8.2)](/filings/0001420720-25-000025.md) | [(3.2)](/filings/0001420720-25-000025.md) | [(7.8) d](/filings/0001558370-25-011888.md) | [(4.0)](/filings/0001104659-26-059416.md) | [(4.4)](/filings/0001104659-26-059416.md) | [(4.9)](/filings/0001104659-26-059416.md) | [(5.2) d](/filings/0001420720-26-000020.md) | [(5.7)](/filings/0001104659-26-059416.md) | [(9.0)](/filings/0001104659-26-059416.md) | [(7.7)](/filings/0001104659-26-059416.md) | [(10.6) d](/filings/0001420720-26-000020.md) |
| Diluted EPS | $ per share | [(4.80)](/filings/0001420720-24-000054.md) | [(4.42)](/filings/0001420720-25-000012.md) | [(0.85)](/filings/0001420720-25-000025.md) | not reported | [(0.46)](/filings/0001420720-25-000043.md) | [(0.48)](/filings/0001420720-26-000004.md) | [(0.49)](/filings/0001104659-26-059416.md) | not reported | [(0.11)](/filings/0001420720-25-000043.md) | [(0.09)](/filings/0001420720-26-000004.md) | [(0.06)](/filings/0001104659-26-059416.md) | not reported |
| Basic EPS | $ per share | [(4.80)](/filings/0001420720-24-000054.md) | [(4.42)](/filings/0001420720-25-000012.md) | [(0.85)](/filings/0001420720-25-000025.md) | not reported | [(0.46)](/filings/0001420720-25-000043.md) | [(0.48)](/filings/0001420720-26-000004.md) | [(0.49)](/filings/0001104659-26-059416.md) | not reported | [(0.11)](/filings/0001420720-25-000043.md) | [(0.09)](/filings/0001420720-26-000004.md) | [(0.06)](/filings/0001104659-26-059416.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.5](/filings/0001558370-23-019043.md) | [2.8](/filings/0001558370-24-000934.md) | [5.3](/filings/0001420720-24-000020.md) | [14.2](/filings/0001558370-25-011888.md) | [11.0](/filings/0001420720-24-000054.md) | [7.0](/filings/0001420720-25-000012.md) | [5.0](/filings/0001420720-25-000025.md) | [8.6](/filings/0001420720-26-000020.md) | [28.1](/filings/0001420720-25-000043.md) | [28.7](/filings/0001420720-26-000004.md) | [47.6](/filings/0001104659-26-059416.md) | [56.4](/filings/0001420720-26-000020.md) |
| Current assets | $m | [23.0](/filings/0001558370-23-019043.md) | [19.7](/filings/0001558370-24-000934.md) | [36.1](/filings/0001420720-24-000020.md) | [15.7](/filings/0001558370-25-011888.md) | [11.7](/filings/0001420720-24-000054.md) | [8.3](/filings/0001420720-25-000012.md) | [6.1](/filings/0001420720-25-000025.md) | [9.7](/filings/0001420720-26-000020.md) | [50.8](/filings/0001420720-25-000043.md) | [53.4](/filings/0001420720-26-000004.md) | [77.3](/filings/0001104659-26-059416.md) | [92.2](/filings/0001420720-26-000020.md) |
| Total assets | $m | [37.7](/filings/0001558370-23-019043.md) | [34.0](/filings/0001558370-24-000934.md) | [50.2](/filings/0001420720-24-000020.md) | [28.7](/filings/0001558370-25-011888.md) | [24.5](/filings/0001420720-24-000054.md) | [21.7](/filings/0001420720-25-000012.md) | [19.1](/filings/0001420720-25-000025.md) | [23.2](/filings/0001420720-26-000020.md) | [64.2](/filings/0001420720-25-000043.md) | [64.4](/filings/0001420720-26-000004.md) | [85.8](/filings/0001104659-26-059416.md) | [99.1](/filings/0001420720-26-000020.md) |
| Current liabilities | $m | [20.7](/filings/0001558370-23-019043.md) | [21.6](/filings/0001558370-24-000934.md) | [21.4](/filings/0001420720-24-000020.md) | [3.8](/filings/0001558370-25-011888.md) | [3.5](/filings/0001420720-24-000054.md) | [4.7](/filings/0001420720-25-000012.md) | [5.4](/filings/0001420720-25-000025.md) | [6.1](/filings/0001420720-26-000020.md) | [6.0](/filings/0001420720-25-000043.md) | [5.9](/filings/0001420720-26-000004.md) | [6.5](/filings/0001104659-26-059416.md) | [11.7](/filings/0001420720-26-000020.md) |
| Total liabilities | $m | [24.5](/filings/0001558370-23-019043.md) | [24.8](/filings/0001558370-24-000934.md) | [25.3](/filings/0001420720-24-000020.md) | [7.4](/filings/0001558370-25-011888.md) | [6.8](/filings/0001420720-24-000054.md) | [7.8](/filings/0001420720-25-000012.md) | [7.7](/filings/0001420720-25-000025.md) | [8.3](/filings/0001420720-26-000020.md) | [8.1](/filings/0001420720-25-000043.md) | [7.8](/filings/0001420720-26-000004.md) | [8.3](/filings/0001104659-26-059416.md) | [13.4](/filings/0001420720-26-000020.md) |
| Shareholders' equity | $m | [13.2](/filings/0001558370-23-019043.md) | [9.2](/filings/0001558370-24-000934.md) | [24.9](/filings/0001420720-24-000020.md) | [21.3](/filings/0001558370-25-011888.md) | [17.8](/filings/0001420720-24-000054.md) | [13.9](/filings/0001420720-25-000012.md) | [11.4](/filings/0001420720-25-000025.md) | [14.9](/filings/0001420720-26-000020.md) | [56.0](/filings/0001420720-25-000043.md) | [56.6](/filings/0001420720-26-000004.md) | [77.5](/filings/0001104659-26-059416.md) | [85.7](/filings/0001420720-26-000020.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,340)](/filings/0001420720-24-000054.md) | [(4,706) d](/filings/0001420720-25-000012.md) | [(3,654) d](/filings/0001420720-25-000025.md) | [(4,854) d](/filings/0001558370-25-011888.md) | [(3,715)](/filings/0001420720-25-000043.md) | [(3,869) d](/filings/0001420720-26-000004.md) | [(3,105) d](/filings/0001104659-26-059416.md) | [(4,615) d](/filings/0001420720-26-000020.md) | [(5,665)](/filings/0001420720-25-000043.md) | [(5,241) d](/filings/0001420720-26-000004.md) | [(6,084) d](/filings/0001104659-26-059416.md) | [(6,228) d](/filings/0001420720-26-000020.md) |
| Capital expenditure | $k | not reported | not reported | [0.0 d](/filings/0001420720-25-000025.md) | [210 d](/filings/0001558370-25-011888.md) | [0.0](/filings/0001420720-25-000043.md) | [1.0 d](/filings/0001420720-26-000004.md) | [14.0 d](/filings/0001104659-26-059416.md) | [1.0 d](/filings/0001420720-26-000020.md) | [32.0](/filings/0001420720-25-000043.md) | [516 d](/filings/0001420720-26-000004.md) | [11.0 d](/filings/0001104659-26-059416.md) | [19.0 d](/filings/0001420720-26-000020.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.8](/filings/0001558370-23-019043.md) | [0.5](/filings/0001558370-24-000934.md) | [0.7](/filings/0001420720-24-000020.md) | [1.2](/filings/0001420720-24-000054.md) | [1.9](/filings/0001420720-25-000012.md) | [3.7](/filings/0001420720-25-000025.md) | [8.6](/filings/0001420720-25-000043.md) | [9.1](/filings/0001420720-26-000004.md) | [9.9](/filings/0001104659-26-059416.md) | [53.0](/filings/0001420720-25-000043.md) | [99.1](/filings/0001420720-26-000004.md) | [120](/filings/0001104659-26-059416.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 64,307,256 at 2026-08-27, from the cover of the [10-K filed 2026-08-28](/filings/0001420720-26-000020.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.